News
KROS
58.28
-1.14%
-0.67
Weekly Report: what happened at KROS last week (0408-0412)?
Weekly Report · 4d ago
Weekly Report: what happened at KROS last week (0401-0405)?
Weekly Report · 04/08 11:43
Weekly Report: what happened at KROS last week (0325-0329)?
Weekly Report · 04/01 11:40
Buy Rating Affirmed for Keros Therapeutics Amid FDA Approval Landscape and Market Opportunity for KER-012
TipRanks · 03/29 07:05
Keros Therapeutics Price Target Maintained With a $105.00/Share by Piper Sandler
Dow Jones · 03/27 16:58
Keros Therapeutics Is Maintained at Overweight by Piper Sandler
Dow Jones · 03/27 16:58
Piper Sandler Maintains Overweight on Keros Therapeutics, Maintains $105 Price Target
Benzinga · 03/27 16:48
Analysts Have Conflicting Sentiments on These Healthcare Companies: Argenx Se (ARGX), Iridex (IRIX) and Keros Therapeutics (KROS)
TipRanks · 03/27 12:40
Piper Sandler Sticks to Its Buy Rating for Keros Therapeutics (KROS)
Piper Sandler analyst Joseph Catanzaro maintained a Buy rating on Keros Therapeutics (KROS – Research Report) The company’s shares closed yesterday at $66.11. The company has a one-year high of $73.00 and a price target of $105.00. Keros is a clinical-stage biopharmaceutical company.
TipRanks · 03/27 11:05
Weekly Report: what happened at KROS last week (0318-0322)?
Weekly Report · 03/25 11:43
Strong Buy Rating for Keros Therapeutics Amid Favorable LR-MDS Treatment Landscape and Regulatory Environment
TipRanks · 03/19 05:37
Weekly Report: what happened at KROS last week (0311-0315)?
Weekly Report · 03/18 11:41
Keros Gets FDA Fast-Track Designation for Lead Drug KER-050
Keros Therapeutics has received U.S. Food and Drug Administration fast-track designation for its lead product candidate for anemia. The designation covers KER-050 for the treatment of anemia in certain patients with the blood disorder. Keros says it plans to work with the FDA on a Phase 3 study.
Dow Jones · 03/14 12:17
Keros Therapeutics Price Target Maintained With a $100.00/Share by Truist Securities
Dow Jones · 03/13 17:33
Truist Securities Reiterates Buy on Keros Therapeutics, Maintains $100 Price Target
Benzinga · 03/13 17:23
Truist Financial Sticks to Their Buy Rating for Keros Therapeutics (KROS)
TipRanks · 03/13 11:35
Weekly Report: what happened at KROS last week (0304-0308)?
Weekly Report · 03/11 11:37
Keros Therapeutics Updates Corporate Presentation Online
TipRanks · 03/06 13:12
Keros Therapeutics (KROS) Gets a Buy from Truist Financial
TipRanks · 03/06 13:06
Keros Therapeutics CMO Simon Cooper Resigns
TipRanks · 03/05 13:12
More
Webull provides a variety of real-time KROS stock news. You can receive the latest news about Keros Therapeutics, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About KROS
Keros Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It is focused on developing and commercializing novel therapeutics to treat a range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (TGF-B), family of proteins. Its lead product candidate, KER-050, is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, and in patients with myelofibrosis. Its second product candidate, KER-012, is being developed for the treatment of pulmonary arterial hypertension, or PAH, and for the treatment of cardiovascular disorders. Its third product candidate, KER-065, is being developed for the treatment of obesity and for the treatment of neuromuscular diseases. KER-050 is designed to raise red blood cell and platelet production by inhibiting the signaling of a subset of the TGF-B family of proteins to promote hematopoiesis.